Back to All Events

Anesthetic and Analgesic Drugs Advisory Committee

The Committee met to discuss a supplemental new drug application (sNDA) for Exparel (bupivacaine liposomal injectable suspension), submitted by Pacira Pharmaceuticals, Inc. (Pacira). A majority of the Committee, 6 of 10 members, voted that the data submitted by Parica for Exparel do not support approval of an additional indication for nerve block.